In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axcan Is Buying European Specialty Pharma Eurand For $583Mx

This article was originally published in The Pink Sheet Daily

Executive Summary

At a 9% premium to Eurand's closing stock price Nov. 30, the value is disappointing, but majority investor Warburg Pincus favors the deal and competitive bids are unlikely.
Advertisement

Related Content

Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
European Cell Therapy Players TiGenix And Cellerix Join Forces For Critical Mass, Cash
European Cell Therapy Players TiGenix And Cellerix Join Forces For Critical Mass, Cash
Abstral Approval May Fetch ProStrakan The Valuation It's After
Abstral Approval May Fetch ProStrakan The Valuation It's After
After Setbacks, Eurand Has Zenpep In Its Step
After Setbacks, Eurand Has Zenpep In Its Step

Topics

Advertisement
UsernamePublicRestriction

Register

PS071548

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel